Levkovitz, Y., Harel, E. V., Roth, Y., Braw, Y., Most, D., Katz, L. N., & Zangen, A. (2009). Brain Stimulation, 2(4), 188-200. This is the first clinical study using the Brainsway® Deep TMS (Tr...Read More
This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Clinical Neurophysiology 118(12):2730-2744 (2007)
Authors: Y Levkovitz, Y Roth, E.V. Harel, Y Braw, A Sheer, A Zangen
Levkovitz, Y., Roth, Y., Harel, E. V., Braw, Y., Sheer, A., & Zangen, A. (2007). Clinical Neurophysiology, 118(12), 2730-2744.
This study examined possible effects of different Brainsway® Deep TMS (Transcranial Magnetic Stimulation) H-coils and different stimulation parameters on healthy individuals. Several parameters relating to health, cognitive and emotional issues were checked .Results were also compared to a standard coil (figure 8) and to a sham coil. This study demonstrated that brain stimulation using the H-coil is feasible, safe and without adverse consequences.